CALGARY, Alberta--(BUSINESS WIRE)--Fluid Biomed Inc., a clinical stage medical device company developing lifesaving products for patients suffering from vascular disease, closed an oversubscribed $27 ...

W.L. Gore & Associates announced today that the FDA approved its Viabahn Fortegra venous stent, formerly known as Viafort.

For about a decade, bioabsorbable stents were hailed as one of the most promising technologies in cardiology. Now, the future prospects of the technology are less than certain after a clinical trial ...

SAN FRANCISCO, CA—At 12 months, a polymer-free, amphilimus-eluting stent was noninferior to a biodegradable-polymer DES in all-comers undergoing PCI, according to results of the PARTHENOPE trial.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

To address concerns of late and very late stent thrombosis associated with first generation drug-eluting stent technology, novel approaches are being tested including stents with bioabsorbable ...

An Abbott Laboratories Inc. ABT drug-coated stent heart device that's designed to be absorbed by the body continues to show no cases of stent-related clots in a small-scale study designed to test the ...